IRulya Therapeutics Quarterly Balance Sheet
NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRulya Therapeutics financial position
As of Sep 30, 2026, IRulya Therapeutics reported total assets of $106.5 million, down 3.1% from a year earlier against total liabilities of $28.4 million. Shareholders' equity was negative at -$65.7 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $39.8 million in cash and equivalents against $0 of debt, a net cash position of $39.8 million.
The current ratio (current assets divided by current liabilities) was 14.72, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
IRulya Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q3 20262026-09-30 | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 39.82M | 115.98M | 18.16M | 5.81M | 6.45M | 16.83M | 7.77M | 6.21M | 2.67M | 7.89M | 21.81M | 20.75M |
| Short-Term Investments | 65.42M | 0 | 0 | 11.94M | — | — | — | 34.57M | 45.17M | 51.55M | 46.01M | 54.31M |
| Total Current Assets | 106.30M | 123.41M | 25.58M | 22.90M | 29.20M | 37.34M | 33.83M | 44.04M | 51.72M | 63.44M | 70.44M | 77.44M |
| Property, Plant & Equipment | 69.00K | 506.00K | 550.00K | 595.00K | 616.00K | 573.00K | 448.00K | 315.00K | 208.00K | 246.00K | 234.00K | 234.00K |
| Goodwill | — | — | — | — | 0 | — | — | 0 | 0 | 0 | 17.25M | 17.63M |
| Intangible Assets | 0 | 0 | 0 | 67.82M | 67.73M | 67.57M | 62.37M | 60.05M | 64.53M | 61.79M | 62.25M | 63.67M |
| Long-Term Investments | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Total Assets | 106.47M | 124.00M | 26.62M | 93.52M | 109.90M | 117.21M | 107.09M | 114.48M | 126.52M | 134.83M | 159.29M | 167.90M |
| Accounts Payable | 1.45M | 4.64M | 5.39M | 2.22M | 3.40M | 1.76M | 3.01M | 2.90M | 1.62M | 2.40M | 2.07M | 2.03M |
| Short-Term Debt | 0 | 0 | 0 | 18.03M | 17.52M | — | — | 0 | — | — | — | — |
| Total Current Liabilities | 7.22M | 8.50M | 8.77M | 43.23M | 26.04M | 7.47M | 8.36M | 7.28M | 5.42M | 10.32M | 9.84M | 9.57M |
| Long-Term Debt | — | — | — | 0 | 0 | 16.99M | 15.27M | 14.32M | 14.90M | 13.83M | 13.52M | 13.43M |
| Total Liabilities | 28.37M | 15.51M | 10.95M | 129.24M | 108.84M | 105.47M | 88.51M | 84.33M | 81.59M | 87.86M | 85.11M | 82.82M |
| Shareholders' Equity | -65.70M | -35.32M | 15.67M | -35.71M | 1.06M | 11.74M | 18.58M | 30.15M | 44.93M | 46.97M | 74.18M | 85.08M |
| Retained Earnings | -527.77M | -500.03M | -424.54M | -460.45M | -420.99M | -407.55M | -391.50M | -376.47M | -364.01M | -358.52M | -330.79M | -319.64M |
| Total Debt | 0 | 0 | 0 | 18.03M | 17.52M | 16.99M | 15.27M | 14.32M | 14.90M | 13.83M | 13.52M | 13.43M |
| Net Cash (Debt) | 105.24M | 115.98M | 18.16M | -274.00K | -11.07M | -163.00K | -7.50M | 26.46M | 32.95M | 45.61M | 54.30M | 61.63M |
| Shares Outstanding | 1.02M | 1.02M | 13.79M | 278.63K | 54.49M | 53.62M | 44.09M | 44.00M | 43.28M | 43.28M | 43.22M | 42.97M |
This table shows 12 quarterly periods of IRulya Therapeutics's balance sheet, from Q3 2026 back to Q4 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow IRLA's reporting calendar. What is a balance sheet?